Mizuho Securities USA LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 46.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 228,188 shares of the company's stock after purchasing an additional 72,091 shares during the period. Johnson & Johnson makes up approximately 0.6% of Mizuho Securities USA LLC's investment portfolio, making the stock its 24th biggest position. Mizuho Securities USA LLC's holdings in Johnson & Johnson were worth $33,001,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Swedbank AB increased its stake in shares of Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after buying an additional 111,570 shares during the period. Principal Financial Group Inc. raised its stake in shares of Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock valued at $562,723,000 after acquiring an additional 329,473 shares during the last quarter. United Bank lifted its holdings in shares of Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company's stock worth $614,000 after purchasing an additional 202 shares during the period. Segall Bryant & Hamill LLC bought a new stake in shares of Johnson & Johnson in the third quarter worth $5,883,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Johnson & Johnson in the third quarter valued at $365,000. Institutional investors own 69.55% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have weighed in on JNJ. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Bank of America lifted their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a research note on Wednesday, March 5th. Wells Fargo & Company lowered their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Finally, StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $171.33.
View Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Stock Performance
JNJ stock traded down $2.15 during midday trading on Tuesday, reaching $161.14. 7,455,754 shares of the company's stock traded hands, compared to its average volume of 7,088,162. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a 50-day moving average price of $157.37 and a two-hundred day moving average price of $156.16. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market capitalization of $388.32 billion, a PE ratio of 24.23, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.29 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.08%. Johnson & Johnson's dividend payout ratio is currently 74.59%.
Insider Buying and Selling
In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
